[Edema tendency, dyspnea and hypertension in the treatment with mirtazapine (Remeron)].
Jensen
J B
JB
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D004417:Dyspnea / Q000139:chemically induced*; D004487:Edema / Q000139:chemically induced*; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D000078785:Mirtazapine
D000317:Adrenergic alpha-Antagonists; D000929:Antidepressive Agents, Tricyclic; D006634:Histamine H1 Antagonists; D008803:Mianserin; D000078785:Mirtazapine
Odemtendens, dyspnø og hypertension ved mirtazapinbehandling (Remeron).